Project Grant R01CA298877
Award Date
4/11/25
Completion Date
3/31/29
Dollars Obligated
$677K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $268,345 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Sanford Burnham Prebys Medical Discovery Institute (SBP) to develop a novel immunotherapy for pancreatic cancer. The key products and services to be delivered under this 2-year grant include: Interrogating the role of the PSGL-1/VISTA axis in regulating T cell responses to pancreatic tumors. This will involve evaluating the immunologic and therapeutic impact of PSGL-1 blockade on...
This Project Grant award of $269,280 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the Translational Genomics Research Institute (TGen) to develop a new therapeutic targeting cellular senescence in pancreatic cancer. The project aims to determine the biological effects of a senescent cell-targeted antibody, SIWA318, and evaluate its ability to enhance the efficacy of standard chemotherapy or immune checkpoint inhibitors in preclinical...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a universal "off-the-shelf" cell therapy utilizing engineered macrophages (immune cells) for the treatment of pancreatic cancer. The $403,687 grant will fund research to demonstrate the anti-tumor effects of macrophages engineered with a chimeric antigen receptor (CAR) targeting phosphatidylserine, a molecule commonly expressed on the surface of cancer cells. The...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to advance the targeted delivery of stromal-targeting therapies for pancreatic ductal adenocarcinoma (PDAC). The $599,474 award, effective September 1, 2024 through August 31, 2029, will support the development of a local controlled-release platform for intratumoral delivery of hyaluronidase. This approach is intended to reduce the dense tumor desmoplasia that acts as a physical...
This $399,970 federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports the development of DUO-207, an innovative nanomedicine to improve treatment for pancreatic cancer. DUO-207 is a fixed-dose combination therapy that delivers gemcitabine and paclitaxel in a 14nm nanoparticle designed to overcome delivery challenges of prior nanomedicines. Key innovations include a patent-pending polymer that protects gemcitabine from rapid...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $654,681 to Case Western Reserve University (CWRU) to develop innovative anticancer nanovaccines utilizing multifunctional ionizable lipid nanoparticles for the curative treatment of pancreatic ductal adenocarcinoma (PDAC). The key objectives are to 1) design and develop multifunctional ionizable ELNP-based peptide vaccines for effective PDAC...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding for the clinical testing of a novel immunotherapeutic approach combining Listeria-Tetanus Toxoid (Listeria-TT) and the chemotherapy drug gemcitabine (GEM) for the treatment of metastatic, unresectable pancreatic ductal adenocarcinoma (PDAC). The key products and services to be delivered under this $294,962 grant, awarded on June 1, 2024, with a completion date of May 31,...
This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" program (CFDA 93.286), provides $640,089 to the University of Texas at Dallas (UTD) to develop advanced photodynamic priming therapies to enhance the efficacy of chemoimmunotherapy for pancreatic ductal adenocarcinoma (PDA). The project aims to use optical molecular imaging to...
This $351,131 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Miami aimed at disrupting the interactions between myeloid-derived suppressor cells (MDSC) and cancer-associated fibroblasts (CAF) in pancreatic cancer. The overarching goals are to: Mechanistically dissect the signaling and spatial interactions between MDSC-derived transmembrane TNF and TNFR2-expressing inflammatory CAFs that govern...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Biology Research (CFDA 93.396) program, provides $667,118 to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at identifying and disabling new pathways for macromolecular recycling in pancreatic cancer. The research team will explore the roles of two key lysosomal hydrolases, PLBD1 and LGMN, in supporting pancreatic cancer growth and metastasis, as well as...